Merida Biosciences
Joe Kovalchin PhD is an accomplished professional in the biotechnology industry with extensive experience in research and development. Currently serving as Vice President of Preclinical Development at Merida Biosciences since October 2024, Joe previously held significant roles including Vice President of Research and Executive Director of Research at Allievex Corporation from November 2019 to October 2024. Joe's career also includes a position as Senior Director of Translational Pharmacology at Amathus Therapeutics from 2017 to November 2019, Director of Research at CoLucid Pharmaceuticals, Inc. from August 2015 to April 2017, and Associate Director of Pharmacology at Eleven Biotherapeutics from May 2010 to August 2015.
This person is not in any teams
This person is not in any offices
Merida Biosciences
Merida Biosciences is a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate pathogenic antibodies that drive disease. The company is advancing a robust pipeline to precisely eliminate the root cause of multiple autoimmune and allergic conditions that are inadequately treated today. Its lead program is designed to specifically and rapidly clear the pathogenic autoantibodies that cause Graves' disease, an autoimmune disorder that affects the thyroid gland. Merida was publicly launched in April 2025 and is based in Cambridge, MA. For more information about Merida, visit www.meridabio.com.